The Trump administration’s cuts to university research grants will make America sicker and poorer in the long run.

Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

AMN Healthcare Services said Mark Foletta was named its new chairman of the board. He succeeds Douglas Wheat, who had served on the board since 1999.

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Truist lowered the firm’s price target on Viking Therapeutics (VKTX) to $95 from $120 and keeps a Buy rating on the shares. The company’s Q4 ...

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...